CLLSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Cellectis S.A.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 20, 2026
$0.93−0.11 (-11.01%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$3.0545 (−76.75%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Cellectis S.A. grew revenue 75.8% to $72.95M over fiscal 2025. Free cash flow was -$41.76M, down 304.7% from a year earlier.
Revenue
$72.95M
+75.8% vs. a year earlier
Operating income
-$33.08M
FY2025
Free cash flow
-$41.76M
-304.7% vs. a year earlier
EPS, diluted
-$0.67
FY2025
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $72.95M
- Net income
- -$67.59M
- EPS, diluted
- -$0.67
- Free cash flow
- -$41.76M
Twelve years at a glance
Fiscal years 2014 to 2025, USD
Revenue
$72.95M+75.8% YoY
Gross profit
$72.95M+75.8% YoY
Operating income
-$33.08M
Net income
-$67.59M
EPS, diluted
-$0.67
Free cash flow
-$41.76M-304.7% YoY
Reported period